ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

The Walgreens Connection: ACS Calls On Drug Stores To Stop Tobacco Sales

April 18, 2014

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014

Niederhuber To Stay at NCI While Obama Makes NIH Plans

January 23, 2009

DRCCA Board, ACCI Agree On New Core Grant Guidelines

February 6, 1981

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

April 9, 2010

Four New Program Announcements For BRMP Trials Issued

October 22, 1982